Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines

Published:2011-09-12 Issue:13 Volume:31 Page:1683-1694
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Grepin R,Guyot M,Jacquin M,Durivault J,Chamorey E,Sudaka A,Serdjebi C,Lacarelle B,Scoazec J-Y,Negrier S,Simonnet H,Pages G

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/onc2011360.pdf

Reference37 articles.

1. Bertini R, Allegretti M, Bizzarri C, Moriconi A, Locati M, Zampella G et al. (2004). Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci USA 101: 11791–11796.

2. Bieche I, Chavey C, Andrieu C, Busson M, Vacher S, Le Corre L et al. (2007). CXC chemokines located in the 4q21 region are upregulated in breast cancer. Endocr Relat Cancer 14: 1039–1052.

3. Cao Y, Wang L, Nandy D, Zhang Y, Basu A, Radisky D et al. (2008). Neuropilin-1 upholds dedifferentiation and propagation phenotypes of renal cell carcinoma cells by activating Akt and sonic hedgehog axes. Cancer Res 68: 8667–8672.

4. Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB et al. (2011). Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest 121: 1313–1328.

5. Cervi D, Yip TT, Bhattacharya N, Podust VN, Peterson J, Abou-Slaybi A et al. (2008). Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 111: 1201–1207.

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options;Cells;2024-05-04

2. A Potent Solution for Tumor Growth and Angiogenesis Suppression via an ELR⁺CXCL-CXCR1/2 Pathway Inhibitor;ACS Medicinal Chemistry Letters;2024-04-03

3. Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001;Journal of Experimental & Clinical Cancer Research;2024-03-19

4. Deciphering resistance mechanisms and novel strategies to overcome drug resistance in ovarian cancer: a comprehensive review;Oncology Research;2024

5. Angiogenesis and Lymphangiogenesis in Medulloblastoma Development;Biology;2023-07-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3